Targeting HIV broadly neutralizing antibody precursors with precision in humans.

Featured News
This is an HIV antibody with a yellow core and pink outer shell.

The GW VRU participated in a phase 1 human clinical trial for a recombinant HIV vaccine. This study has promising results and provides proof-of-concept for Env trimer-based GT approaches to activate broadly neutralizing antibody (bnAb) precursors and induce affinity maturation on the path toward mature bnAbs. The structural analyses demonstrate that precise targeting of bnAb precursors with atomic-level accuracy can now be achieved, heralding a new era of vaccine design.

(image from Alamy Stock Photo)

Click here to read the article.
HIV Vaccine

Latest News

Lassa Virus under a microscope
Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate
This was a phase 1, double-blind trial to examine the safety and immunogenicity of a replication-competent recombinant vesicular stomatitis virus-vectored vaccine to reduce the risk of infection and severe illness from Lassa Fever.
An omicron COVID virus. A gray virus with red and orange projections.
The effect of Omicron BA.1-based booster mRNA vaccination on the incidence of COVID-19
The GW VRU is pleased to share the findings from a Phase 2 clinical trial that evaluated the effects of omicron-based COVID-19 vaccines in providing an increased level of protection against COVID-19 infection. This study adds to the evidence that matching COVID-19 vaccines to the circulating…
Picture of antibodies.
HIV vaccine using mRNA-encoded nanoparticles showed to be safe and well-tolerated
The GW VRU participated in IAVI-G002 as a clinical site for a phase 1 human clinical trial. This study evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens and first-boosting immunogens (IAVI-G002).